These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26358992)

  • 1. The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.
    Özyilmaz A; Boersma C; Visser ST; Postma MJ; de Jong-van den Berg LT; Lambers-Heerspink HJ; de Jong PE; Gansevoort RT
    Eur J Prev Cardiol; 2016 May; 23(8):847-55. PubMed ID: 26358992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
    Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
    Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
    Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS).
    Lee JW; You NY; Kim Y; Kim Y; Kim J; Kang HT
    Nutr Metab Cardiovasc Dis; 2019 Jul; 29(7):701-709. PubMed ID: 31133496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
    Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
    Ko MJ; Kim YJ; Park CM; Lee SM; Lee WJ; Pencina MJ; Navar-Boggan AM; Park DW
    Am Heart J; 2015 Sep; 170(3):598-605.e7. PubMed ID: 26385045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
    Ong HT
    QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
    Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
    Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
    Okopień B; Krysiak R; Kowalski J; Madej A; Belowski D; Zieliński M; Herman ZS
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):377-86. PubMed ID: 16116345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
    Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events.
    Özyilmaz A; Bakker SJ; de Zeeuw D; de Jong PE; Gansevoort RT;
    Nephrol Dial Transplant; 2013 Nov; 28(11):2805-15. PubMed ID: 23975751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.